all report title image
  • Published On : Sep 2022
  • Code : CMI5258
  • Industry : Pharmaceutical
  • Pages : 156
  • Formats :
Ingographics Image

A protein called beta-catenin is crucial for growth and development of embryos. The CTNNB1 gene in humans encodes the protein catenin beta. It is a protein with two functions that is also known as beta-catenin 1 and is involved in the control and coordination of cells, gene transcription, and cell adhesion. Additionally, it promotes cell adhesion, which is essential for the development of structures like bones and skin. The activity of genes in cells is regulated in part by beta-catenin. It functions by attaching to certain molecules known as transcription factors, which bind to Deoxyribonucleic acid (DNA) and influence how an embryo grows into a fully formed human being. Additionally, beta catenin regulates cell division and growth (proliferation). B-catenin is a crucial nuclear effector of canonical Wntsignaling in the nucleus and a structural component of cadherin-based adherens junctions. B-catenin structural and signaling imbalance frequently causes sickness and dysfunctional growth linked to metastasis and cancer. The primary effector in the canonical Wnt cascade is B-catenin, which transmits the signal to the nucleus and causes transcription of Wnt-specific genes that regulate cell fate decisions in a variety of cells and organs.

Market Dynamics

Key players operating in market are expected to drive the market growth during the forecast period, owing to increase in cancer patients. For instance, according to data published in January 2022, by the American Cancer Society, in 2022 in the U.S., there are about 106,180 cases of colon cancer. Moreover, according to data published on March 2021, by World Health Organization, states that, in 2020, there were 2.3 million women diagnosed with breast cancer globally and 685 000 deaths globally.

Key features of the study:

  • This report provides in-depth analysis of the global beta catenin market , and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global beta catenin market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Boston Biomedical Inc, Dicerna Pharmaceuticals Inc., Marina Biotech Inc., Propanac Biopharma Inc, Warp Drive Bio Inc., prism pharma co ltd, , aileron therapeutics inc, MD2 Biosciences Inc, WntRx Pharmaceuticals Inc, Sapience Therapeutics Inc, and Venn Therapeutics LLC
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global beta catenin market  report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global beta catenin market

Detailed Segmentation:

  • Global Beta Catenin Market, By Type:
    • BBI-801
    • Exisulind
    • M-101
    • Nefopam Hydrochloride
    • Others
  • Global Beta Catenin Market, By Application:
    • Dermatology
    • Oncology
    • Genetic Disorder
    • Others
  • Global Beta Catenin Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Boston Biomedical Inc *
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Dicerna Pharmaceuticals Inc.
    • Marina Biotech Inc.
    • Propanac Biopharma Inc.
    • Warp Drive Bio Inc
    • prism pharma co Ltd.
    • aileron therapeutics Inc.
    • MD2 Biosciences Inc.
    • WntRx Pharmaceuticals Inc.
    • Sapience Therapeutics Inc.
    • Venn Therapeutics LLC

“*” marked represents similar segmentation in other categories in the respective section.

Detailed Segmentation:

  • Global Beta Catenin Market, By Type:
    • BBI-801
    • Exisulind
    • M-101
    • Nefopam Hydrochloride
    • Others
  • Global Beta Catenin Market, By Application:
    • Dermatology
    • Oncology
    • Genetic Disorder
    • Others
  • Global Beta Catenin Market, By Region:
    • North America
      •  By Type
        • BBI-801
        • Exisulind
        • M-101
        • Nefopam Hydrochloride
        • Others
      • By Application
        • Dermatology
        • Oncology
        • Genetic Disorder
        • Others
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Type
        • BBI-801
        • Exisulind
        • M-101
        • Nefopam Hydrochloride
        • Others
      • By Application
        • Dermatology
        • Oncology
        • Genetic Disorder
        • Others
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Type
        • BBI-801
        • Exisulind
        • M-101
        • Nefopam Hydrochloride
        • Others
      • By Application
        • Dermatology
        • Oncology
        • Genetic Disorder
        • Others
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Type
        • BBI-801
        • Exisulind
        • M-101
        • Nefopam Hydrochloride
        • Others
      • By Application
        • Dermatology
        • Oncology
        • Genetic Disorder
        • Others
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Type
        • BBI-801
        • Exisulind
        • M-101
        • Nefopam Hydrochloride
        • Others
      • By Application
        • Dermatology
        • Oncology
        • Genetic Disorder
        • Others
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Type
        • BBI-801
        • Exisulind
        • M-101
        • Nefopam Hydrochloride
        • Others
      • By Application
        • Dermatology
        • Oncology
        • Genetic Disorder
        • Others
      • By Country
        • South Africa
        • Central Africa
        • North Africa

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo